The analyst's clinical trial report, “Neuromyelitis Optica (Devic’s Syndrome) - Global Clinical Trials Review, H2, 2021" provides an overview of Neuromyelitis Optica (Devic’s Syndrome) Clinical trials scenario. This report provides top line data relating to the clinical trials on Neuromyelitis Optica (Devic’s Syndrome) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Report GuidanceClinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Neuromyelitis Optica (Devic’s Syndrome) to Central Nervous System Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Neuromyelitis Optica (Devic’s Syndrome) to Central Nervous System Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials
Prominent Drugs
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About the Publisher
Contact Us
Source
List of Tables
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, Global, Clinical Trials by Region, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2021*
Proportion of Neuromyelitis Optica (Devic’s Syndrome) to Central Nervous System Clinical Trials, G7 Countries (%), 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2021*
Proportion of Neuromyelitis Optica (Devic’s Syndrome) to Central Nervous System Clinical Trials, E7 Countries (%), 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2016-2020
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2021*
List of Figures
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, North America, Top Countries (%), 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2021*
Proportion of Neuromyelitis Optica (Devic’s Syndrome) to Central Nervous System Clinical Trials, G7 Countries (%), 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2021*
Proportion of Neuromyelitis Optica (Devic’s Syndrome) to Central Nervous System Clinical Trials, E7 Countries (%), 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2016-2020
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2021*
Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2021*
Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- F. Hoffmann-La Roche Ltd
- AstraZeneca Plc
- The Lundbeck Foundation
- Boston Pharmaceuticals Inc
- Hbm Holdings Ltd
- PPD Inc
- Takeda Pharmaceutical Co Ltd
- Yantai Rongchang Pharmaceutical Co Ltd
- Bionure Farma SL
- Pamplona Capital Management LLP
